secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001654954-23-003357
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics receives US patent for IV levosimendan in PH-HFpEF, expiring Dec 2040
--------------------------------------------------------------------------------

- U.S. Patent No. 11,607,412 covers IV levosimendan for pulmonary hypertension with HFpEF.
- Patent protection extends until December 2040, strengthening IP for levosimendan.
- No FDA-approved treatments exist for PH-HFpEF, which affects >1.6M North Americans.
- Levosimendan combines K+ATP channel activation and Ca++ sensitization, distinct MoA.
- HELP Study showed 29-meter improvement in 6-minute walk distance vs placebo (p=0.03).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423003357/0001654954-23-003357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423003357/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-003357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer